Staff Profile

Ruth Plummer is Professor of Experimental Cancer Medicine, Newcastle University and an honorary consultant medical oncologist in Newcastle Hospitals NHS Foundation Trust. She is Director of the Sir Bobby Robson Cancer Trials Research Centre within the Northern Centre for Cancer Care, which is a dedicated clinical trials unit based within the regional cancer centre. She leads the Newcastle Experimental Cancer Medicine Centre and also the CRUK Newcastle Cancer Centre. She trained at Cambridge and Oxford Universities obtaining both a medical degree and scientific PhD before moving back home to Newcastle and settling with her family in Northumberland.

Her clinical practice involves leading on the systemic therapies for skin cancer, with a portfolio of trials across all phases of drug development. In addition she runs a phase I all-comers practice, taking responsibility for one of the most active phase I unit’s in the UK.

Her research interests are in the field of DNA repair and early phase clinical trials of novel agents, taking the first in class PARP inhibitor into the clinic in 2003, ATR inhibitor in 2012 and MCT1 inhibitor in 2014.

This research is either based in the Sir Bobby Robson Cancer Trials Research Centre or in the Newcastle University Centre for Cancer of which she is a deputy director. Nationally she chairs the MRC Ex[erimenatal Medicine Panel, and sits as a member of Cancer Research UK’s Clinical Research Committee and Research Careers Committee. She is a also member of the MRC Precision Medicine Group and the NIHR EME Committee.

She was elected a Fellow of the Academy of Medical Sciences in 2018 for her work developing PARP inhibitors as novel cancer treatments and in 2021 she was awarded the ESMO-TAT Lifetine Acheivement award for her work is early phase trials. In 2022 she was awarded an MBE in the Queen's Jubilee honours for services to medicine

Roles and Responsibilities

• Honorary Consultant at Newcastle Hospitals NHS Foundation Trust  

SCOPUS: Click here.

• Articles

  • Lim JX, Lai CY, Mallett GE, McDonald D, Hulme G, Laba S, Shapanis A, Payne M, Patterson W, Alexander M, Coxhead J, Filby A, Plummer R, Lovat PE, Sciume G, Healy E, Amarnath S. Programmed cell death-1 receptor-mediated regulation of Tbet⁺NK1.1^- innate lymphoid cells within the tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America 2023, 120(18), e2216587120.
  • Rae S, Plummer E, Fitzgerald L, Hogarth L, Bridgewood A, Brown-Schofield L, Graham J, Haigh S, McAnulty C, Drew Y, Haris N, Bashir S, Plummer R, Greystoke A. Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders. Journal of Cancer Research and Clinical Oncology 2023, 149, 16355–16363.
  • Rasco DW, Medina T, Corrie P, Pavlick AC, Middleton MR, Lorigan P, Hebert C, Plummer R, Larkin J, Agarwala SS, Daud AI, Qiu J, Bozon V, Kneissl M, Barry E, Olszanski AJ. Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology 2023, 92, 15-28.
  • Coyle V, Forde C, McAuley DF, Wilson RH, Clarke M, Plummer R, Grayson M, McDowell C, Agus A, Doran A, Thomas AL, Barnes RA, Adams R, Chau I, Storey D, McMullan R. Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH): a randomized non-inferiority trial. Clinical Microbiology and Infection 2023, 30(1), 92-99.
  • Bai X, Shaheen A, Grieco C, d'Arienzo PD, Mina F, Czapla JA, Lawless AR, Bongiovanni E, Santaniello U, Zappi H, Dulak D, Williamson A, Lee R, Gupta A, Li C, Si L, Ubaldi M, Yamazaki N, Ogata D, Johnson R, Park BC, Jung S, Madonna G, Hochherz J, Umeda Y, Nakamura Y, Gebhardt C, Festino L, Capone M, Ascierto PA, Johnson DB, Lo SN, Long GV, Menzies AM, Namikawa K, Mandala M, Guo J, Lorigan P, Najjar YG, Haydon A, Quaglino P, Boland GM, Sullivan RJ, Furness AJS, Plummer R, Flaherty KT. Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study. eClinical Medicine 2023, 65, 102290.
  • Halford S, Veal GJ, Wedge SR, Payne GS, Bacon CM, Sloan P, Dragoni I, Heinzmann K, Potter S, Salisbury BM, Chenard-Poirier M, Greystoke A, Howell EC, Innes WA, Morris K, Plummer C, Rata M, Petrides G, Keun HC, Banerji U, Plummer R. A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer. Clinical Cancer Research 2023, 29(8), 1429-1439.
  • Lopez J, Lai-Kwon J, Molife R, Welsh L, Tunariu N, Roda D, Fernandez-Garcia P, Lladó V, McNicholl A, Roselló C, Taylor R, Azaro A, Ahnert JR, Sludden J, Veal G, Plummer R, Urruticoechea A, Lahuerta A, Mujika K, Escriba P. A Phase 1/2A trial of idroxioleic acid: First-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma. British Journal of Cancer 2023, 129, 811-818.
  • Menne T, Slade D, Savage J, Johnson S, Irving J, Kearns P, Plummer R, Shenton G, Veal GJ, Vormoor B, Vormoor J, Billingham L. Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial. BMJ Open 2022, 12, e059872.
  • Coombes RC, Badman P, Lozano-Kuehne JP, Macpherson IRJ, Zubairi I, Baird RD, Garcia-Corbacho J, Cresti N, Plummer R, Armstrong AC, Allerton R, Landers D, McLellan L, Lim A, Mouliere F, Seckl M. Results of the Phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nature Communications 2022, 13, 3246.
  • Telli ML, Tolaney SM, Shapiro GI, Middleton M, Lord SR, Arkenau HT, Tutt A, Abramson V, Dean E, Haddad TC, Wesolowski R, Ferrer-Playan J, Goddemeier T, Grombacher T, Dong J, Fleuranceau-Morel P, Diaz-Padilla I, Plummer R. Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. n p j Breast Cancer 2022, 8(1), 45.
  • Plummer R, Dean E, Arkenau H-T, Redfern C, Spira AI, Melear JM, Chung KY, Ferrer-Playan J, Goddemeier T, Locatelli G, Dong J, Fleuranceau-Morel P, Diaz-Padilla I, Shapiro GI. A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. Lung Cancer 2022, 163, 19-26.
  • Middleton MR, Dean E, Evans TRJ, Shapiro GI, Pollard J, Hendriks BS, Falk M, Diaz-Padilla I, Plummer R. Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours. British Journal of Cancer 2021, 125(4), 510-519.
  • Dummer R, Hauschild A, Santinami M, Atkinson V, Mandalà M, Kirkwood JM, Sileni VC, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Gasal E, Tan M, Long GV, Schadendorf D. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. New England Journal of Medicine 2020, 383(12), 1139-1148.
  • Forde C, McMullan R, Clarke M, Wilson RH, Plummer R, Grayson M, McDowell C, Agus A, Doran A, McAuley DF, Thomas AL, Barnes RA, Adams R, Chau I, Coyle V. Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial. Trials 2020, 21(1), 431.
  • McNeillis R, Greystoke A, Walton J, Bacon C, Keun H, Sitkos A, Petrides G, Leech G, Jenkinson F, Bowron A, Halford S, Plummer R. A case of malignant hyperlactaemic acidosis appearing on treatment with the mono-carboxylase transporter 1 inhibitor AZD3965. British Journal of Cancer 2020, 122(1272), 1141-1145.
  • Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, Kefford R, Dummer R, Kirkwood JM, Long GV. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF^V600E or BRAF^V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. The Lancet Oncology 2019, 20(5), 701-710.
  • Verykiou S, Alexander M, Edwards N, Plummer R, Chaudhry B, Lovat PE, Hill DS. Harnessing autophagy to overcome MEK-inhibitor induced resistance in metastatic melanoma. British Journal of Dermatology 2019, 180(2), 346-356.
  • Findlay SG, Gill JH, Plummer R, De-Santis C, Plummer C. Chronic cardiovascular toxicity in the older oncology patient population. Journal of Geriatric Oncology 2019, 10(5), P685-689.
  • Chung HC, Arkenau H-T, Lee J, Rha SY, Oh D-Y, Wyrwicz L, Kang Y-K, Lee K-W, Infante JR, Lee SS, Kemeny M, Keilholz U, Melichar B, Mita A, Plummer R, Smith D, Gelb AB, Xiong H, Hong J, Chand V, Safran H. Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: Phase 1b results from the JAVELIN Solid Tumor trial. Journal for ImmunoTherapy of Cancer 2019, 7(1), 30.
  • Mak G, Soria J-C, Blagden SP, Plummer R, Fleming RA, Nebot N, Zhang J, Mazumdar J, Rogan D, Gazzah A, Rizzuto I, Greystoke A, Yan L, Tolson J, Auger KR, Arkenau H-T. A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. British Journal of Cancer 2019, 120, 975-981.
  • Twelves C, Anthoney A, Savulsky CI, Guo M, Reyderman L, Cresti N, Semiglazov V, Timcheva C, Zubairi I, Morrison R, Plummer R, Evans TRJ. A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. British Journal of Cancer 2019, 120, 579–586.
  • Danilenko M, Stamp E, Stocken DD, Husain A, Zangarini M, Cranston A, Stones R, Sinclair N, Hodgson K, Bowett SA, Roblin D, Traversa S, Plummer R, Veal G, Langtry JAA, Ashworth A, Burn J, Rajan N. Targeting tropomyosin receptor kinase in cutaneous CYLD defective tumors (TRAC): A randomised placebo-controlled early phase trial with pegcantratinib. JAMA Dermatology 2018, 154(8), 913-921.
  • Fordham SE, Blair HJ, Elstob CJ, Plummer R, Drew Y, Curtin NJ, Heidenreich O, Pal D, Jamieson D, Park C, Pollard J, Fields S, Milne P, Jackson GH, Marr HJ, Menne T, Jones GJ, Allan JM. Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase. Blood Advances 2018, 2(10), 1157-1169.
  • Cranston A, Stocken DD, Stamp E, Roblin D, Hamlin J, Langtry J, Plummer R, Ashworth A, Burn J, Rajan N. Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial. Trials 2017, 18, 111.
  • Greystoke A, Steele N, Arkenau H-T, Blackhall F, Md Haris N, Lindsay CR, Califano R, Voskoboynik M, Summers Y, So K, Ghiorghiu D, Dymond AW, Hossack S, Plummer R, Dean E. SELECT-3: A phase i study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. British Journal of Cancer 2017, 117(7), 938-946.
  • Long GV, Hauschild A, Santinami M, Atkinson V, Mandal M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM. Adjuvant Dabrafenib plus Trametinib in stage III BRAF-mutated melanoma. New England Journal of Medicine 2017, 377(19), 1813-1823.
  • Escudier B, Faivre S, Van Cutsem E, Germann N, Pouget J-C, Plummer R, Vergote I, Thistlethwaite F, Bjarnason GA, Jones R, Mackay H, Edeline J, Fartoux L, Hirte H, Oza A. A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers. Targeted Oncology 2017, 12(5), 655-661.
  • McConnell AT, Ellis R, Pathy B, Plummer R, Lovat PE, O'Boyle G. The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma. British Journal of Dermatology 2016, 175(6), 1210-1220.
  • Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Gogov S, Pallaud C, Yi TT, Mone M, Chang ALS, Cornelis F, Kudchadkar R, Trefzer U, Lear JT, Sellami D, Migden MR. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. Journal of the American Academy of Dermatology 2016, 75(1), 113-125.e5.
  • Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. British Journal of Cancer 2016, 114(7), 723-730.
  • Massey AJ, Stephens P, Rawlinson R, McGurk L, Plummer R, Curtin NJ. mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition. Molecular Oncology 2016, 10(1), 101-112.
  • Ogle LF, Orr JG, Willoughby CE, Hutton C, McPherson S, Plummer R, Boddy AV, Curtin NC, Jamieson D, Reeves HL. Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for hepatocellular carcinoma?. Journal of Hepatology 2016, 65(2), 305-313.
  • Dent BM, Ogle LF, O'Donnell RL, Hayes N, Mallick U, Curtin NJ, Boddy AV, Plummer ER, Edmondson RJ, Reeves HL, May FEB, Jamieson D. High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. International Journal of Cancer 2016, 138(1), 206-216.
  • Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, Brown SR, Buckland S, Bulbeck H, Chalmers AJ, Clack G, Cranston AN, Damstrup L, Ferraldeschi R, Forster MD, Golec J, Hagan RM, Hall E, Hanauske AR, Harrington KJ, Haswell T, Hawkins MA, Illidge T, Jones H, Kennedy AS, McDonald F, Melcher T, O'Connor JPB, Pollard JR, Saunders MP, Sebag-Montefiore D, Smitt M, Staffurth J, Stratford IJ, Wedge SR, NCRI CTRad Acad-Pharma Joint Worki. Clinical development of new drug-radiotherapy combinations. Nature Reviews. Clinical Oncology 2016, 13(10), 627-642.
  • Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, Ohman R, Plummer R, Eberhardt WEE, Fukuoka K, Gaafar RM, Lafitte JJ, Hillerdal G, Chu Q, Buikhuisen WA, Lubiniecki GM, Sun X, Smith M, Baas P. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncology 2015, 16(4), 447-456.
  • Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncology 2015, 16, 716-728.
  • Middleton MR, Friedlander P, Hamid O, Daud A, Plummer R, Falotico N, Chyla B, Jiang F, McKeegan E, Mostafa NM, Zhu M, Qian J, Mckee M, Luo Y, Giranda VL, McArthur GA. Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. Annals of Oncology 2015, 26(10), 2173-2179.
  • Ring A, Wheatley D, Hatcher H, Laing R, Plummer R, Uttenreuther-Fischer M, Temple G, Pelling K, Schnell D. Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer. Clinical Cancer Research 2015, 21(12), 2737-2744.
  • Ramlau R, Thomas M, Novello S, Plummer R, Reck M, Kaneko T, Lau MR, Margetts J, Lunec J, Nutt J, Scagliotti GV. Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker. Clinical Lung Cancer 2015, 16(5), 348-357.
  • Kendra KL, Plummer R, Salgia R, O'Brien MER, Paul EM, Suttle AB, Compton N, Xu CF, Ottesen LH, Villalona-Calero MA. A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics 2015, 14(2), 461-469.
  • Murray J, Thomas H, Berry P, Kyle S, Patterson M, Jones C, Los G, Hostomsky Z, Plummer ER, Boddy AV, Curtin NJ. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. British Journal of Cancer 2014, 110, 1977-1984.
  • Plummer R. Poly(ADP-ribose)polymerase (PARP) Inhibitors: From Bench to Bedside. Clinical Oncology 2014, 26(5), 250-256.
  • Cassier PA, Polivka V, Judson I, Soria JC, Penel N, Marsoni S, Verweij J, Schellens JH, Morales-Barrera R, Schoffski P, Voest EE, Gomez-Roca C, Evans TRJ, Plummer R, Gallerani E, Kaye SB, Olmos D. Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database. Annals of Oncology 2014, 25(6), 1222-1228.
  • Calvert H, Twelves C, Ranson M, Plummer R, Fettner S, Pantze M, Ling J, Hamilton M, Lum BL, Rakhit A. Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer. Anti-Cancer Drugs 2014, 25(7), 832-840.
  • Garcia VM, Olmos D, Gomez-Roca C, Cassier PA, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto AT, Schoffski P, Marsoni S, Schellens JHM, Penel N, Voest E, Evans J, Plummer R, Wilson RH, Soria JC, Tabernero J, Verweij J, Kaye SB. Dose-Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. Clinical Cancer Research 2014, 20(22), 5663-5671.
  • Gupta A, Love S, Schuh A, Shanyinde M, Larkin JM, Plummer R, Nathan PD, Danson S, Ottensmeier CH, Lorigan P, Collins L, Wise A, Asher R, Lisle R, Middleton MR. DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. Annals of Oncology 2014, 25(5), 968-974.
  • Plummer R, Lorigan P, Brown E, Zaucha R, Moiseyenko V, Demidov L, Soriano V, Chmielowska E, Andres R, Kudryavtseva G, Kahatt C, Szyldergemajn S, Extremera S, de Miguel B, Cullell-Young M, Calvert H. Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma. British Journal of Cancer 2013, 109(6), 1451-1459.
  • Massard C, Margetts J, Amellal N, Drew Y, Bahleda R, Stevens P, Armand JP, Calvert H, Soria JC, Coronado C, Kahatt C, Alfaro V, Siguero M, Fernandez-Teruel C, Plummer R. Phase I study of PM00104 (Zalypsis (R)) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors. Investigational New Drugs 2013, 31(3), 623-630.
  • O'Boyle G, Swidenbank I, Marshall H, Barker CE, Armstrong J, White SA, Fricker SP, Plummer R, Wright M, Lovat PE. Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070. British Journal of Cancer 2013, 108(8), 1634-1640.
  • Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, Mulligan E, Curtin N, Wang D, Dewji R, Abbattista A, Gallo J, Calvert H. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemotherapy and Pharmacology 2013, 71(5), 1191-1199.
  • Venugopal B, Baird R, Kristeleit RS, Plummer R, Cowan R, Stewart A, Fourneau N, Hellemans P, Elsayed Y, Mcclue S, Smit JW, Forslund A, Phelps C, Camm J, Evans TRJ, de Bono JS, Banerji U. A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors. Clinical Cancer Research 2013, 19(15), 4262-4272.
  • Olmos D, A'Hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schoffski P, Ang JE, Penel N, Schellens JH, del Conte G, Brunetto AT, Evans TRJ, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB. Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors. Journal of Clinical Oncology 2012, 30(9), 996-1004.
  • Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, Boitano M, Calabro L, De Rossi C, Di Giacomo AM, Ferrucci PF, Ridolfi L, Altomonte M, Miracco C, Balestrazzi A, Maio M. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunology, Immunotherapy 2012, 61(1), 41-48.
  • Leach MO, Morgan B, Tofts PS, Buckley DL, Huang W, Horsfield MA, Chenevert TL, Collins DJ, Jackson A, Lomas D, Whitcher B, Clarke L, Plummer R, Judson I, Jones R, Alonzi R, Brunner T, Koh DM, Murphy P, Waterton JC, Parker G, Graves MJ, Scheenen TWJ, Redpath TW, Orton M, Karczmar G, Huisman H, Barentsz J, Padhani A, Expt Canc Med Ctr Imaging Network. Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. European Radiology 2012, 22(7), 1451-1464.
  • Cerbinskaite A, Mukhopadhyay A, Plummer ER, Curtin NJ, Edmondson RJ. Defective homologous recombination in human cancers. Cancer Treatment Reviews 2012, 38(2), 89-100.
  • Mukhopadhyay A, Plummer ER, Elattar A, Soohoo S, Uzir B, Quinn JE, McCluggage WG, Maxwell P, Aneke H, Curtin NJ, Edmondson RJ. Clinicopathological Features of Homologous Recombination-Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival. Cancer Research 2012, 72(22), 5675-5682.
  • Elattar A, Warburton KG, Mukhopadhyay A, Freer RM, Shaheen F, Cross PA, Plummer ER, Robson CN, Edmondson RJ. Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecologic Oncology 2012, 124(1), 142-147.
  • Drew Y, Mulligan EA, Vong W, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ. Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2. Journal of the National Cancer Institute 2011, 103(4), 334-346.
  • Shaheen FS, Znojek P, Fisher A, Webster M, Plummer R, Gaughan L, Smith GCM, Leung HY, Curtin NJ, Robson CN. Targeting the DNA Double Strand Break Repair Machinery in Prostate Cancer. PLoS One 2011, 6(5), e20311.
  • Hottiger MO, Boothby M, Koch-Nolte F, Luscher B, Martin NMB, Plummer R, Wang ZQ, Ziegler M. Progress in the Function and Regulation of ADP-Ribosylation. SCIENCE SIGNALING 2011, 4(174).
  • Zaremba T, Thomas HD, Cole M, Coulthard SA, Plummer ER, Curtin NJ. Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers. Biochemical Journal 2011, 436(3), 671–679.
  • Salazar R, Plummer R, Oaknin A, Robinson A, Pardo B, Soto-Matos A, Yovine A, Szyldergemajn S, Calvert AH. Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas. Investigational New Drugs 2011, 29(6), 1406-1413.
  • Harrington KJ, Billingham LJ, Brunner TB, Burnet NG, Chan CS, Hoskin P, Mackay RI, Maughan TS, Macdougall J, McKenna WG, Nutting CM, Oliver A, Plummer R, Stratford IJ, Illidge T, NCRI Clinical Translational Radiot. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. British Journal of Cancer 2011, 105(5), 628-639.
  • Mahadevan D, Plummer R, Squires MS, Rensvold D, Kurtin S, Pretzinger C, Dragovich T, Adams J, Lock V, Smith DM, Von Hoff D, Calvert H. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Annals of Oncology 2011, 22(9), 2137-2143.
  • Plummer R, Wilson RH, Calvert H, Boddy AV, Griffin M, Sludden J, Tilby MJ, Eatock M, Pearson DG, Ottley CJ, Matsumura Y, Kataoka K, Nishiya T. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. British Journal of Cancer 2011, 104(4), 593-598.
  • Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono J, Plummer R. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. Journal of Clinical Oncology 2010, 28(25), 3965-3972.
  • Azribi F, Razak ARA, Bough G, Lee D, Rowe D, Bown N, Dildey P, Clark S, Plummer R. Extraosseous Pericardial Ewing's Sarcoma. Journal of Clinical Oncology 2010, 28(4), e48-e50.
  • Plummer R, Woll P, Fyfe D, Boddy AV, Griffin M, Hewitt P, Carmichael J, Namouni F, Cohen M, Verrill M. A phase I and pharmacokinetic study of lxabepilone in combination with carboplatin in patients with advanced solid malignancies. Clinical Cancer Research 2008, 14(24), 8288-8294.
  • Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I, McHugh P, Margison GP, McGown G, Thorncroft M, Watson AJ, Boddy AV, Calvert AH, Harris AL, Newell DR, Curtin NJ. Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O⁶-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clinical Cancer Research 2005, 11(9), 3402-3409.
  • Boddy AV, Plummer ER, Todd R, Sludden J, Griffin MJ, Robson L, Cassidy J, Bissett D, Bernareggi A, Verrill MW, Calvert AH. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clinical Cancer Research 2005, 11(21), 7834-7840.
  • Plummer ER, Rees C, Hughes AN, Beale P, Highley MS, Trigo J, Gokul S, Judson I, Calvert AH, Jackman A, Mitchell F, Smith R, Douglass E. A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor. Clinical Cancer Research 2003, 9(4), 1313-1322.
  • Hughes AN, Calvert PM, Azzabi A, Plummer ER, Johnson R, Rusthoven J, Griffin MJ, Fishwick KA, Boddy AV, Verrill MW, Calvert AH. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. Journal of Clinical Oncology 2002, 20(16), 3533-3544.
  • Plummer ER, Ghielmini M, Calvert PM, Voi M, Renard J, Gallant G, Gupta E, Calvert AH, Sessa C. Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. Clinical Cancer Research 2002, 8(9), 2788-2797.

• Conference Proceedings (inc. Abstracts)

  • Plummer R, Halford S, Jones P, Wedge S, Hirschberg S, Veal G, Payne G, Chenard-Poirier M, Keun H, Banerji U. A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours. In: International Congress on Targeted Anticancer Therapies (TAT) 2018. 2018, Paris: Elsevier BV.
  • Lear J, Guminski A, Gutzmer R, Migden M, Kudchadkar R, Lewis K, Dirix L, Plummer R, Stratigos A, Chang AL, Trefzer U, Loquai C, Kaatz M, Combemale P, Mone M, Castro H, Yi T, Sellami D, Dummer R. Sonidegib safety in patients with locally advanced Basal Cell Carcinoma and efficacy based on tumor aggressiveness. In: 16th World Congress on Cancers of the Skin 2016. 2016, Vienna, Austria: Lippincott Williams & Wilkins, Ltd.
  • Dean E, Steele N, Arkenau HT, Blackhall F, Haris NM, Lindsay C, Rafii S, Califano R, Plummer R, Voskoboynik M, Summers YJ, Ghiorghiu D, Dymond A, So K, Greystoke A. SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting. In: 41st ESMO Congress (ESMO 2016). 2016, Copenhagen, Denmark: Oxford University Press.
  • Dummer R, Migden M, Guminski A, Gutzmer R, Kudchadkar R, Lewis K, Dirix L, Combemale P, Trefzer U, Loquai C, Kaatz M, Chang AL, Stratigos A, Plummer R, Mone M, Castro H, Yi T, Sellami D, Lear J. Investigator-assessed efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma and metastatic basal cell carcinoma: results of the BOLT 30-month analysis. In: 16th World Congress on Cancers of the Skin 2016. 2016, Vienna, Austria: Lippincott Williams & Wilkins, Ltd.
  • Pearson RA, Thelwall PE, Snell J, McKenna J, Pieniazek P, Fitzgerald E, Heer R, McMenemin RM, Pedley ID, Azzabi A, Maxwell RJ, Newell DR, Plummer ER, Frew JA. Evaluation of early responses to neoadjuvant chemotherapy in muscle-invasive bladder cancer using a dynamic contrast-enhanced MRI and diffusion-weighted MRI: MARBLE study. In: Genitourinary Cancers Symposium 2016. 2016, San Francisco, California: Journal of Clinical Oncology.
  • Pearson RA, Thelwall PE, Snell J, McKenna J, Pieniazek P, Fitzgerald EL, Heer R, McMenemin RM, Pedley ID, Azzabi AS, Newell H, Maxwell RJ, Plummer ER, Frew JA. Evaluation of early response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using dynamic contrast-enhanced MRI and diffusion weighted MRI: MARBLE study. In: 2016 Genitourinary Cancers Symposium. 2016, San Francisco: American Society of Clinical Oncology.
  • Brown S, Brass D, Rajan N, Oliphant T, Plummer R, Langtry J. Advanced basal cell carcinomas treated by vismodegib and Mohs micrographic surgery: does neoadjuvant treatment have a role?. In: British Association of Dermatologists 96th Annual Meeting. 2016, Birmingham, UK: Wiley-Blackwell.
  • Escriba PV, Busquets X, Llado V, Roda D, Jimenez B, Molife R, Plummer R, Rodon J, Azaro A, Sicart E, Klumper E. Pivotal role of sphingomyelin synthase (SGMS) expression and activity in glioma patient survival presents a potential therapeutic target. In: 51st ASCO Annual Meeting. 2015, Chicago, Illinois: American Society of Clinical Oncology.
  • Rasco DW, Middleton MR, Gonzalez R, Corrie P, Pavlick A, Lorigan P, Plummer R, Gore M, Herbert C, Agarwala SS, Logan TF, Khleif SN, Papadopoulos KP, Rangachari L, Suri A, Xu Q, Kneissl M, Bozon V, Olszanski AJ. Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma. In: European Cancer Congress 2015. 2015, Vienna, Austria: Elsevier.
  • Verykiou S, Hill D, Plummer R, Lovat P. Contribution of autophagy to the survival of melanoma-initiating CD271-positive subpopulations. In: British Society of Investigative Dermatology Annual Meeting 2015. 2015, Southampton, UK: Wiley-Blackwell.
  • Patel PM, Ottensmeier C, Mulatero C, Lorigan P, Plummer R, Hannaman D, Cunnell M, Metheringham R, Brentville V, Daniels I, Machado L, Durrant LG. An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells in vivo, in fully resected melanoma patients. In: 51st Annual Meeting of American Society Of Clinical Oncology. 2015, Chicago, Illnois: American Society of Clinical Oncology.
  • Arkenau HT, Gazzah A, Plummer R, Blagden SP, Mak G, Soria JC, Greystoke A, Rizzuto I, Rogan D, Mazumdar J, Laubscher K, Auger KR, Swartz LS, Mattern ML, Nebot N, Singh RP, Fleming RA, Yan L. A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors. In: American Society of Clinical Oncology (ASCO) 2015 Annual Meeting. 2015, Chicago, Illinois, USA: American Society of Clinical Oncology.
  • Molife LR, King J, Smith A, D'arcangelo M, Brown N, Diamantis N, Lane H, Hoffmann AHS, Engelhardt M, Plummer R, Kristeleit R. A first-in-human study of intravenous BAL101553, a novel microtobule inhibitor, in patients with advanced solid tumors. In: 13th International Congress on Targeted Anticancer Therapies (TAT 2015). 2015, Paris, France: Oxford University Press.
  • Roda D, Drew Y, Azaro A, Smith AD, Greystoke A, Sicart E, Escriba PV, Busquets X, Llado V, Tur V, Klumper E, Ahnert JR, Molife LR, Plummer R. A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM). In: 2015 American Society of Clinical Oncology Annual Meeting. 2015, Chicago, Illinois, USA: American Society of Clinical Oncology.
  • Jaime JC, Paz-Ares L, Provencio M, Bennouna J, Ponce-Aix S, Plummer R, Delord JP, Isambert N, Trigo JM, Belli R, Brienza S, Zanna C, Purcea D, Calvo V, Alonso M, Senellart H, Hiret S, Marti AM, Felip E. The HALO study: A phase I-II of the oral HSP90 inhibitor Debio0932 in combination with SOC in first- and second-line therapy of advanced NSCLC. In: 2014 Annual Meeting of the American Society of Clinical Oncology. 2014, Chicago, Illinois: American Society of Clinical Oncology.
  • McConnell A, Ellis R, O'Boyle G, Plummer R, Verykiou S, Lovat P. Prognostic significance of CXCR4 expression in cutaneous melanoma. In: British Society of Investigative Dermatology Annual Meeting. 2014, Newcastle upon Tyne: Wiley-Blackwell.
  • Patel PM, Durrant LG, Ottensmeier C, Mulatero C, Lorigan P, Plummer R, Cunnell M, Metheringham R, Brentville V, Machado L, Daniels I, Hannaman D. Phase I trial of ImmunoBody in melanoma patients. In: 2014 Annual Meeting of the American Society of Clinical Oncology. 2014, Chicago, Illinois: American Society of Clinical Oncology.
  • Plummer R, Dua D, Cresti N, Suder A, Drew Y, Prathapan V, Stephens P, Thornton JK, de las Heras B, Ink B, Lee L, Matijevic M, McGrath S, Sarker D. Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma. In: 39th ESMO Congress. 2014, Madrid, Spain: Oxford University Press.
  • Rajan N, Brown S, Ward S, Pieniazek P, Hainsworth P, Douglas F, Husain A, Plummer R. Mesenteric cysts in Gorlin syndrome: a mimic of metastatic disease. In: Abstracts for the British Association of Dermatologists 94th Annual Meeting. 2014, Glasgow: Wiley-Blackwell.
  • Lear J, Fife K, Gore M, Guerrero-Urbano T, Herd R, Plummer R, Seguin NB, Hansson J, Mitchell L, Starnawski M, Hauschild A. Interim analysis of STEVIE, a single-arm, open-label, multicentre study to evaluate the safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma. In: British Association of Dermatologists 94th Annual Meeting. 2014, Glasgow, UK: Wiley-Blackwell Publishing Ltd.
  • Middleton M, Rasco DW, Olszanski AJ, Corrie P, Lorigan P, Plummer R, Larkin J, Pavlick A, Zhou X, Yuan Z, Gangolli E, Kneissl M, Bozon V, Gonzalez R. First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma. In: 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2014, Barcelona, Spain: Elsevier.
  • Ogle L, Jamieson D, O'Donnell R, Dent B, Boddy A, Curtin N, Plummer R, Reeves H, Clinical and Translational Group. Detection of circulating tumour cells (CTCS) in hepatocellular (HCC) cancer patients using the ImageStream^x. In: The International Liver Congress 2014: 49th Annual Meeting of the European Association for the Study of the Liver. 2014, London: Elsevier BV.
  • Dent B, O'Donnell RL, Ogle LF, Rourke ED, Ramesh HP, Moat M, Hayes N, Mallick UK, May FE, Reeves HL, Curtain NJ, Edmondson RJ, Boddy AV, Plummer R, Jamieson D. Detection and characterization of circulating tumor cells by imaging flow cytometry. In: AACR Annual Meeting 2014. 2014, San Diego, CA: American Association for Cancer Research.
  • Gauler TC, Besse B, Novello S, Smit EF, Plummer ER, Delord JP, Nicodemo M, Santoro A, Barone C, Marchetti P, Conte PF, De Jonge MJ, Awada A, Mariani M, Jannuzzo MG, Petroccione A, Ceruti R, Davite C, Eberhardt WEE. Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC). In: 2013 ASCO Annual Meeting. 2013, Chicago, Illinois, USA: American Society of Clinical Oncology.
  • Ahmad S, Qian W, Ellis SG, Khattak MA, Gupta A, Thillai K, Board RE, Nobes J, Dalgleish A, Grumett SA, Maraveyas A, Danson S, Talbot T, Marples M, Plummer R, Kumar S, Middleton MR, Larkin JMG, Ottensmeier C, Corrie P. Ipilimumab in the real world: The UK expanded access programme (EAP) experience in advanced melanoma. In: 2013 ASCO Annual Meeting. 2013, Chicago, Illinois, USA: American Society Clinical Oncology.
  • Lear JT, Gore M, Guerrero-Urbano T, Herd R, Plummer R, Basset-Seguin N, Hansson J, Mitchell L, Starnawski M, Hauschild A, Fife K. Interim analysis of STEVIE, a single-arm, open-label, multicentre study to evaluate the safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma. In: British Association of Dermatologists 93rd Annual Meeting. 2013, Liverpool, UK: Wiley-Blackwell.
  • Plummer ER. Inhibitor of ATR (Ataxia Telangiectasia and RAD3 Related) Kinase. In: 11th International Congress on Targeted Anticancer Therapies (TAT 2013). 2013, Paris, France: Oxford University Press.
  • Gupta A, Love S, Schuh A, Collins L, Thomason A, Asher R, Lisle R, Churchman M, Shanyinde M, Plummer R, Nathan PD, Danson S, Ottensmeier CHH, Lorigan P, Larkin JMG, Middleton MR. DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma. In: 2013 ASCO Annual Meeting. 2013, Chicago, Illinois, USA: American Society of Clinical Oncology.
  • Molife LR, Roxburgh P, Wilson RH, Gupta A, Middleton MR, Evans TRJ, Michie CO, Mateo J, Crawford D, Eatock MM, Saka W, Cresti N, Drew Y, Giordano H, Despain D, Simpson D, Allen AR, Jaw-Tsai SS, Plummer R. A phase I study of oral rucaparib in combination with carboplatin. In: 2013 ASCO Annual Meeting. 2013, Chicago, Illinois, USA: American Society of Clinical Oncology.
  • Roxburgh P, Molife LR, Gupta A, Wilson R, Evans TRJ, Cresti N, Giordano H, Simpson D, Jaw-Tsai S, Plummer R. A phase 1 study of oral rucaparib in combination with carboplatin. In: European Cancer Congress 2013. 2013, Amsterdam, Netherlands: Elsevier.
  • Coupe N, Roxburgh P, Drew Y, Molife LR, Wilson R, Spicer J, Gupta A, Simpson D, Giordano H, Plummer R. A Phase 1 Study of Oral or Intravenous Rucaparib in Combination in Combination with Platinum-Containing Chemotherapeutic Regimens: Analysis of Patients with Ovarian or Peritoneal Tumors. In: 18th International Meeting of the European Society of Gynaecological Oncology (ESGO). 2013, Liverpool, UK: Lippincott Williams & Wilkins.
  • Plummer R. Understanding failure of PARP inhibition in the clinic. In: 10th International Symposium on Targeted Anticancer Therapies. 2012, Amsterdam, Netherlands: Oxford University Press.
  • Stephens P, Massey A, Plummer R, Curtin N. Single Agent Activity of the Novel Checkpoint 1 Kinase Inhibitor V158411. In: EUROPEAN JOURNAL OF CANCER. 2012, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND: ELSEVIER SCI LTD.
  • Molife LR, Mateo J, McGoldrick T, Krebs M, Drew Y, Banerjee SN, Nicum S, Ranson M, Rustin GJS, Sessa C, Plummer R, Leunen K, Friedlander M, Swaisland H, Burke W, McCormack P, Pemberton K, Tchakov I, Kaye SB, Gourley C. Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations. In: JOURNAL OF CLINICAL ONCOLOGY. 2012, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA: AMER SOC CLINICAL ONCOLOGY.
  • Savulsky C, Nasim M, Plummer R, Evans J, Morrison R, Anthoney A, Haney S, Madi A, Johnston C, Carter D, Reydermann L, Gopalakrishna P, Wanders J, Twelves C. Phase Ib dose-escalation study of eribulin in combination with capecitabine in patients with advanced/metastatic cancer. In: Deutsche, Österreichische und Schweizerische Gesellschaften für Hämatologie und Onkologie. 2012, Stuttgart, Germany: S. Karger AG.
  • Gupta A, Moreno V, Dean EJ, Drew Y, Nicum S, Ranson M, Plummer R, Swaisland H, Burke W, McCormack P, Tchakov I, Middleton MR, Kaye SB, Molife LR. Phase I study to determine the bioavailability and tolerability of a tablet formulation of the PARP inhibitor olaparib in patients with advanced solid tumors: Dose-escalation phase. In: JOURNAL OF CLINICAL ONCOLOGY. 2012, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA: AMER SOC CLINICAL ONCOLOGY.
  • Twelves CJ, Nasim M, Anthoney A, Cresti N, Savulsky C, Johnston C, Reyderman L, Wanders J, Plummer R, Evans TRJ. Pharmacokinetics of eribulin mesilate in combination with capecitabine in patients with advanced/metastatic cancer: Results from a phase IB dose-escalation study. In: 37th Congress of the European Society for Medical Oncology (ESMO). 2012, Vienna, Austria: Oxford University Press.
  • Shaw H, Larkin J, Corrie P, Ellis S, Nobes J, Marshall E, Kumar S, Danson S, Plummer R, Nathan P. Ipilimumab for advanced melanoma in an expanded access programme (EAP): Ocular, mucosal and acral subtype UK experience. In: 37th Congress of the European Society for Medical Oncology (ESMO). 2012, Vienna, Austria: Oxford University Press.
  • Vormoor B, Wilkinson S, Harvey F, Plummer R, Curtin N. Ewing's Sarcoma Cells Can Be Sensitized to Temozolomide and to a Lesser Extent to Radiotherapy by Co-treatment with a PARP-inhibitor (AG014699). In: 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2012, Dublin, Ireland: Pergamon.
  • Mukhopadhyay A, Plummer R, Elatter A, Soohoo S, Uzir B, Quinn J, Aneke H, Curtin NJ, Edmondson RJ. Clinicopathological features of homologous recombination deficient epithelial ovarian cancers: Sensitivity to PARP inhibitors, platinum and survival. In: Blair Bell Research Society Annual Academic Meeting. 2012, London, UK: Wiley-Blackwell Publishing Ltd.
  • Mukhopadhyay A, Plummer ER, Elatter A, Soohoo S, Uzir B, Quinn JE, McCluggage WG, Maxwell P, Aneke H, Curtin NJ, Edmondson RJ. Clinicopathological features of homologous recombination deficient epithelial ovarian cancers: Sensitivity to PARP inhibitors, platinum and survival. In: AACR 103rd Annual Meeting. 2012, Chicago, Illinois, USA: American Association for Cancer Research.
  • Nasim MY, Plummer R, Evans TRJ, Morrison R, Anthoney DA, Haney S, Madi A, Savulsky CI, Johnston C, Carter D, Reyderman L, Gopalakrishna P, Wanders J, Twelves C. A phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer. In: JOURNAL OF CLINICAL ONCOLOGY. 2012, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA: AMER SOC CLINICAL ONCOLOGY.
  • Plummer ER. Targeting DNA damage repair beyond PARP - further drugs or targets in development. In: Annals of Oncology: 9th International Symposium on Targeted Anticancer Therapies. 2011, Paris, France: Oxford University Press.
  • Plummer R. Poly(ADP-ribose) polymerase inhibitor development: are we in the right direction?. In: 9th Conference on Madrid Breast Cancer. 2011, Madrid, Spain: BioMed Central Ltd.
  • Shalinsky DR, Wang DD, Kern KA, English P, Curtin NJ, Plummer R. Poly(ADP ribose) polymerase (PARP) inhibition in peripheral blood lymphocytes (PBLs): Does it reflect PARP inhibition in tumor?. In: JOURNAL OF CLINICAL ONCOLOGY. 2011, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA: AMER SOC CLINICAL ONCOLOGY.
  • Drew Y, Ledermann JA, Jones A, Hall G, Jayson GC, Highley M, Rea D, Glasspool RM, Halford SER, Crosswell G, Colebrook S, Boddy AV, Curtin NJ, Plummer ER. Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer. In: JOURNAL OF CLINICAL ONCOLOGY. 2011, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA: AMER SOC CLINICAL ONCOLOGY.
  • Kendra K, Plummer R, Salgia R, O'Brien MER, Paul EM, Suttle AB, Ottesen LH, Villalona-Calero MA. Phase I Dose-Finding Study for Pazopanib (P) and Paclitaxel (T) in Combination in the First-line Setting in Patients (pts) With Advanced Solid Tumours. In: EUROPEAN JOURNAL OF CANCER. 2011, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND: ELSEVIER SCI LTD.
  • Razak AA, Nutt J, O'Toole K, Black F, Cole M, Plummer R, Lunec J, Calvert H. Expression of methylthioadenosine phosphorylase (MTAP) in malignant pleural mesothelioma (MPM) and its implication for pemetrexed-based chemotherapy. In: EJC Supplements: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2010, Berlin, Germany: Pergamon.
  • Plummer R. Encouraging first experiences with PARP inhibitors. In: Annals of Oncology: 35th European Society for Medical Oncology (ESMO) Congress. 2010, Milan, Italy: Oxford University Press.
  • Danielli R, Queirolo P, Testori A, Plummer R, Razis E, Sileni VC, Calabro L, Di Giacomo AM, Ridolfi R, Maio M. Ipilmumab in pretreated metastatic uveal melanoma patients: Safety and clinical efficacy. In: Annals of Oncology: 11th National Congress of Medical Oncology. 2009, Milan, Italy: Oxford University Press.
  • Danielli R, Queirolo P, Testori A, Plummer R, Razi E, Sileni VC, Calabro L, Di Giacomo AM, Ridolfi R, Maio M. Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy. In: EJC Supplements: 15th Congress of the European Cancer Organization. 2009, Berlin, Germany: Pergamon.
  • Plummer R. Phase I and II clinical trials of the potent intravenous PARP inhibitor, AG014699. In: ANNALS OF ONCOLOGY. 2008, GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND: OXFORD UNIV PRESS.
  • Calvert H, Curtin N, Plummer R. PARP INHIBITORS IN OVARIAN CANCER. In: ANNALS OF ONCOLOGY. 2008, GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND: OXFORD UNIV PRESS.
  • Plummer R, Vida L, Perrett R, Spicer J, Stopfer P, Shahidi M, Temple G, Futreal A, Calvert H, de Bono J. A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor. In: EJC SUPPLEMENTS. 2007, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND: PERGAMON-ELSEVIER SCIENCE LTD.

• Notes

  • Williams KC, Gault A, Anderson AE, Stewart CJ, Lamb CA, Speight RA, Rajan N, Plummer R, Pratt AG. Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations. Frontiers in Immunology 2023, 14, 1122430.
  • McAteer MA, O'Connor JPB, Koh DM, Leung HY, Doran SJ, Jauregui-Osoro M, Muirhead N, Brew-Graves C, Plummer ER, Sala E, Ng T, Aboagye EO, Higgins GS, Punwani S. Introduction to the National Cancer Imaging Translational Accelerator (NCITA): a UK-wide infrastructure for multicentre clinical translation of cancer imaging biomarkers. British Journal of Cancer 2021, 125, 1462-1465.
  • Massard C, Margetts J, Amellal N, Drew Y, Bahleda R, Stephens P, Armand JP, Calvert H, Soria JC, Coronado C, Kahatt C, Alfaro V, Siguero M, Fernandez-Teruel C, Plummer R. Erratum to: Phase I study of PM00104 (Zalypsis (R)) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors (vol 31, pg 623, 2013 Doi: 10.1007/s10637-012-9843-5). Investigational New Drugs 2013, 31(3), 799.

• Reviews

  • Beale S, Dickson R, Bagust A, Blundell M, Dundar Y, Boland A, Marshall E, Plummer R, Proudlove C. Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal. PharmacoEconomics 2013, 31(12), 1121-1129.
  • Plummer R. Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?. Breast Cancer Research and Treatment 2011, 13(4), 218.
  • Mukhopadhyay A, Curtin N, Plummer R, Edmondson RJ. PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY 2011, 118(4), 429-432.
  • Plummer ER. Inhibition of poly(ADP-ribose) polymerase in cancer. Current Opinion in Pharmacology 2006, 6(4), 364-368.